Deep Lens has been a shining success story in the Columbus start-up scene over the last year. Since its inception in 2017, Deep Lens has established itself as the leading disruptor in a huge market, by using AI and other technologies to advance and accelerate clinical trial recruitment in oncology, specifically commencing with the pathology of the patient and initiated at the time of diagnosis. To date, the company has raised more than $20 million from leading Silicon Valley, East Coast and Ohio-based venture capital firms, and has executed agreements with major pharma, biotech, and provider clients across the globe.
Click here to read the complete article.
News release excerpt provided by Yahoo Finance.
Originally published September 26, 2019.